
Identifying Patients Who Will Benefit From Intensified Prostate Cancer Treatment
Identifying men with high-risk, non-metastatic prostate cancer who will truly benefit from intensified treatment from therapeutic approaches like Zytiga (abiraterone) plus standard therapy is a growing need, as 60% of patients do well on standard therapy …